表紙
市場調査レポート

末梢神経障害性疼痛:パイプライン製品の分析

Peripheral Neuropathic Pain - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 276009
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
末梢神経障害性疼痛:パイプライン製品の分析 Peripheral Neuropathic Pain - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 70 Pages
概要

末梢神経障害性疼痛は組織の損傷に伴って慢性的に疼痛が起きている状態で、アルコール依存症、糖尿病、化学療法、感染症、手術および多発性硬化症などの要因によっても発症します。灼熱痛、刺痛、しびれなどが症状で、非ステロイド系の抗炎症剤、抗けいれん剤、抗うつ剤などが治療に使われます。

当レポートでは、末梢神経障害性疼痛に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

末梢神経障害性疼痛の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

末梢神経障害性疼痛:企業で開発中の治療薬

末梢神経障害性疼痛:大学/機関で研究中の治療薬

末梢神経障害性疼痛:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

末梢神経障害性疼痛:企業で開発中の製品

末梢神経障害性疼痛:大学/機関で研究中の製品

末梢神経障害性疼痛の治療薬開発に従事している企業

  • Achelios Therapeutics, Inc.
  • AnaBios Corporation
  • Chromocell Corporation
  • Eli Lilly and Company
  • GW Pharmaceuticals Plc
  • Nektar Therapeutics
  • Phosphagenics Limited
  • Spherium Biomed S.L.
  • Sunovion Pharmaceuticals Inc.
  • Zynerba Pharmaceuticals, Inc.

末梢神経障害性疼痛:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

末梢神経障害性疼痛:最近のパイプライン動向

末梢神経障害性疼痛:休止中のプロジェクト

末梢神経障害性疼痛:開発が中止された製品

末梢神経障害性疼痛:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7888IDB

Summary

Global Markets Direct's, 'Peripheral Neuropathic Pain - Pipeline Review, H1 2016', provides an overview of the Peripheral Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain
  • The report reviews pipeline therapeutics for Peripheral Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peripheral Neuropathic Pain therapeutics and enlists all their major and minor projects
  • The report assesses Peripheral Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathic Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathic Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral Neuropathic Pain Overview
  • Therapeutics Development
    • Pipeline Products for Peripheral Neuropathic Pain - Overview
    • Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis
  • Peripheral Neuropathic Pain - Therapeutics under Development by Companies
  • Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
  • Peripheral Neuropathic Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Peripheral Neuropathic Pain - Products under Development by Companies
  • Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes
  • Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development
    • Achelios Therapeutics, Inc.
    • AnaBios Corporation
    • Chromocell Corporation
    • Eli Lilly and Company
    • GW Pharmaceuticals Plc
    • Nektar Therapeutics
    • Phosphagenics Limited
    • Spherium Biomed S.L.
    • Sunovion Pharmaceuticals Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Peripheral Neuropathic Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AXPN-03 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CC-8464 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-2230 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • duloxetine hydrochloride DR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ECL-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nabiximols - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NKTR-171 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxycodone ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Pain - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SP-15001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYN-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Peripheral Neuropathic Pain - Recent Pipeline Updates
  • Peripheral Neuropathic Pain - Dormant Projects
  • Peripheral Neuropathic Pain - Discontinued Products
  • Peripheral Neuropathic Pain - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2014: Phosphagenics Provides Update on TPM/Oxycodone patch
      • Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral Neuropathic Pain, H1 2016
  • Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Peripheral Neuropathic Pain - Pipeline by Achelios Therapeutics, Inc., H1 2016
  • Peripheral Neuropathic Pain - Pipeline by AnaBios Corporation, H1 2016
  • Peripheral Neuropathic Pain - Pipeline by Chromocell Corporation, H1 2016
  • Peripheral Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2016
  • Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H1 2016
  • Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H1 2016
  • Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H1 2016
  • Peripheral Neuropathic Pain - Pipeline by Spherium Biomed S.L., H1 2016
  • Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016
  • Peripheral Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Peripheral Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2016
  • Peripheral Neuropathic Pain - Dormant Projects, H1 2016
  • Peripheral Neuropathic Pain - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Peripheral Neuropathic Pain, H1 2016
  • Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top